Dyadic signals 40% transferrin cost reduction as it pursues non-dilutive capital amid going concern disclosure (NASDAQ:DYAI)
· seekingalpha.com
Dyadic (DYAI) Q2 2026 earnings call: commercialization progress, 80% transferrin productivity gain, and going-concern/financing risks.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...